ALKS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

35.930

Open

35.770

VWAP

35.26

Vol

2.62M

Mkt Cap

5.83B

Low

34.871

Amount

92.27M

EV/EBITDA(TTM)

29.05

Total Shares

166.68M

EV

6.83B

EV/OCF(TTM)

26.66

P/S(TTM)

3.77

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Show More

Events Timeline

(ET)

2026-05-05

07:10:00

Sees FY26 Adjusted EBITDA of $370M to $410M

2026-05-05

07:10:00

Q1 Revenue Reaches $392.9M, Exceeds Consensus

2026-04-16 (ET)

2026-04-16

07:10:00

Alkermes to Present New Alixorexton Data at 2026 Neurology Annual Meeting

2026-04-14 (ET)

2026-04-14

07:10:00

Alkermes Publishes 56-Week Post Hoc Analysis of Lybalvi

2026-04-01 (ET)

2026-04-01

07:10:00

Alkermes Initiates Brilliance Studies Evaluating New Drug

News

seekingalpha

05-04seekingalpha

Alkermes Q1 Earnings Announcement Scheduled

NASDAQ.COM

04-07NASDAQ.COM

Analysis of XBI ETF Trading Dynamics

stocktwits

03-31stocktwits

Alkermes Shares Surge 15% Following Lilly-Centessa Deal

Newsfilter

03-12Newsfilter

Alkermes Launches Mental Health Nursing Grant Program

seekingalpha

02-25seekingalpha

Alkermes 2026 Financial Outlook and Acquisition Progress

NASDAQ.COM

02-25NASDAQ.COM

Alkermes Reports Decline in Q4 Earnings

12 Analyst Rating

Wall Street analysts forecast ALKS stock price to rise

10 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

37.00

Averages

46.20

High

58.00

Current: 0.000

Low

37.00

Averages

46.20

High

58.00

Needham

Needham

Buy

maintain

$45 -> $50

AI Analysis

2026-05-06

New

Reason

Needham

Needham

Price Target

$45 -> $50

AI Analysis

2026-05-06

New

maintain

Buy

Reason

Needham raised the firm's price target on Alkermes (ALKS) to $50 from $45 and keeps a Buy rating on the shares after its Q1 results. The stock is up significantly year to date, partially benefiting from the acquisition of Centessa (CNTA) by Eli Lilly (LLY), though it remains undervalued considering its profitable base business is expected to generate $370M to $410M in adjusted EBITDA this year and It's increasing lead over Centessa with expanded Phase 2b ORX750 following the acquisition, the analyst tells investors in a research note.

UBS

Ashwani Verma

Buy

maintain

$42 -> $48

2026-05-06

New

Reason

UBS

Ashwani Verma

Price Target

$42 -> $48

2026-05-06

New

maintain

Buy

Reason

UBS analyst Ashwani Verma raised the firm's price target on Alkermes to $48 from $42 and keeps a Buy rating on the shares. Alkermes is gaining increased investor attention following large-cap pharma interest in competing orexin programs, with broader validation of its pipeline and expanded indication strategy beyond hypersomnolence supporting improved long-term growth potential and strategic optionality, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALKS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Alkermes Plc (ALKS.O) is 158.73, compared to its 5-year average forward P/E of 98.56. For a more detailed relative valuation and DCF analysis to assess Alkermes Plc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

98.56

Current PE

158.73

Overvalued PE

247.78

Undervalued PE

-50.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

5.76

Current EV/EBITDA

-37.08

Overvalued EV/EBITDA

77.33

Undervalued EV/EBITDA

-65.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.56

Current PS

3.13

Overvalued PS

4.40

Undervalued PS

2.73

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks with strong buy rating

Intellectia · 44 candidates

Market Cap: >= 2.00BAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceYtd Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

SGHC Ltd

6.37B

News Corp

14.36B

Ultragenyx Pharmaceutical Inc

2.37B

QXO Inc

14.89B

BioCryst Pharmaceuticals Inc

2.27B

Alkermes Plc

5.54B

show me a good buy

Intellectia · 15 candidates

Market Cap: >= 5.00BPrice: $10.00 - $80.00Analyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNASTarget Price Upside Potential: MoreAbovePrice, AbovePriceMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: $10.00 - $35.00Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Summit Therapeutics Inc

14.67B

Terns Pharmaceuticals Inc

6.09B

Alkermes Plc

5.84B

Jfrog Ltd

5.80B

BP PLC

118.27B

Golar LNG Ltd

5.45B

what stock should I day trade right now

Intellectia · 83 candidates

Price: $10.00 - $80.00Price Change Pct: >= $8.00Relative Vol: >= 3Moving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Apellis Pharmaceuticals Inc

2.18B

Centessa Pharmaceuticals PLC

4.03B

Sensei Biotherapeutics Inc

31.71M

Vor Biopharma Inc

610.34M

Firefly Aerospace Inc

3.78B

Alkermes Plc

5.02B

Intellectia · 54 candidates

Market Cap: >= 2.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Hesai Group

3.73B

Riot Platforms Inc

5.75B

Spyre Therapeutics Inc

2.48B

Immunovant Inc

5.24B

Edgewise Therapeutics Inc

2.98B

Nuvalent Inc

7.99B

stocks with the most upside

Intellectia · 13 candidates

Market Cap: >= 5.00BAnalyst Consensus: Strong BuyEps Ttm: >= 0Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Uber Technologies Inc

175.08B

Axon Enterprise Inc

48.48B

Cheniere Energy Inc

44.62B

Nebius Group NV

24.90B

Futu Holdings Ltd

23.11B

Viper Energy Inc

14.18B

reduce to top 5

Intellectia · 35 candidates

Analyst Consensus: Strong BuyRelative Vol: >= 1.50Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Viper Energy Inc

14.18B

Cipher Mining Inc

7.00B

Alkermes Plc

5.59B

CG Oncology Inc

4.61B

California Resources Corp

4.37B

Alliance Laundry Holdings Inc

4.27B

Best stocks with highest gains

Intellectia · 14 candidates

Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Amgen Inc

185.02B

Vertex Pharmaceuticals Inc

117.00B

Takeda Pharmaceutical Co Ltd

51.17B

Biontech SE

29.61B

Royalty Pharma PLC

22.93B

Moderna Inc

19.46B

best Biotechnology/Health Tech gainers

Intellectia · 14 candidates

Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Amgen Inc

185.02B

Vertex Pharmaceuticals Inc

117.00B

Takeda Pharmaceutical Co Ltd

51.17B

Biontech SE

29.61B

Royalty Pharma PLC

22.93B

Moderna Inc

19.46B

top Biotechnology/Health Tech For gainers

Intellectia · 14 candidates

Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Amgen Inc

185.02B

Vertex Pharmaceuticals Inc

117.00B

Takeda Pharmaceutical Co Ltd

51.17B

Biontech SE

29.61B

Royalty Pharma PLC

22.93B

Moderna Inc

19.46B

market cap can be as low as possible

Intellectia · 26 candidates

Market Cap: >= 0Relative Vol: >= 1.50Beta: LowRisk, ModerateRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: 5 - 25

Ticker

Name

Market Cap$

Abbott Laboratories

209.93B

NetEase Inc

83.31B

Garmin Ltd

39.35B

Telefonaktiebolaget LM Ericsson

31.60B

Royalty Pharma PLC

22.93B

Check Point Software Technologies Ltd

18.72B

Whales Holding ALKS

Avoro Capital Advisors LLC

Soleus Capital Management, L.P.

Frazier Life Sciences Management, LP

Rice Hall James & Associates, LLC

Baker Bros. Advisors LP

RTW Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Alkermes Plc (ALKS) stock price today?

The current price of ALKS is 34.99 USD — it has decreased -1.16

What is Alkermes Plc (ALKS)'s business?

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

What is the price predicton of ALKS Stock?

Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is46.20 USD with a low forecast of 37.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alkermes Plc (ALKS)'s revenue for the last quarter?

Alkermes Plc revenue for the last quarter amounts to 392.91M USD, increased 28.19

What is Alkermes Plc (ALKS)'s earnings per share (EPS) for the last quarter?

Alkermes Plc. EPS for the last quarter amounts to -0.40 USD, decreased -407.69

How many employees does Alkermes Plc (ALKS). have?

Alkermes Plc (ALKS) has 2050 emplpoyees as of May 11 2026.

What is Alkermes Plc (ALKS) market cap?

Today ALKS has the market capitalization of 5.83B USD.